More articles from Molecular Markers for Detection and Predicting Therapeutic Response -- Oral Presentations - Proffered Abstracts

Abstract #1894: The 70-gene MammaPrint® signature predicts response to neoadjuvant chemotherapy in breast cancer
Marieke Straver, Annuska Glass, Juliane Hannemann, Jelle Wesseling, Marc van de Vijver, Emiel Rutgers, Marie-Jeanne Vrancken Peeters, Harm van Tinteren, Laura van 't Veer, Sjoerd Rodenhuis

Cancer Research May 2009, 69 (9 Supplement) 1894;
Abstract #1899: Impact of MET amplification on gastric cancer: A novel prognostic marker and a potential therapeutic arget
Jeeyun Lee, Joon Park, Jin Seo, Hun Jun, Chang-Seok Ki, Se Park, Young Park, Ho Lim, Min Choi, Jae Bae, Tae Sohn, Jae Noh, Sung Kim, Kyoung-Mee Kim, Cheol Park, Won Kang

Cancer Research May 2009, 69 (9 Supplement) 1899;
Abstract #1896: PIK3CA mutations do not confer resistance to the EGFR-inhibitor cetuximab in chemorefractory metastatic colorectal cancer
Wendy De Roock, Jef De Schutter, Hans Prenen, Bart Jacobs, Bart Biesmans, Bart Claes, Diether Lambrechts, Eric Van Cutsem, Sabine Tejpar

Cancer Research May 2009, 69 (9 Supplement) 1896;
Abstract #1902: An FGFR3 mutation in cells obtained from voided urine is a strong predictor of recurrent bladder cancer
Ellen Zwarthoff, Madelon van der Aa, Theo van der Kwast, Ewout Steyerberg, Chris Bangma, Tahlita Zuiverloon

Cancer Research May 2009, 69 (9 Supplement) 1902;
Abstract #1900: Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas
Antoine Italiano, Laurence Bianchini, Frederique Keslair, Nathalie Cardot, Claire Mainguene, Dominique Ranchere-Vince, Philippe Terrier, Agnes Leroux, Jean-Michel Coindre, Florence Pedeutour

Cancer Research May 2009, 69 (9 Supplement) 1900;
Abstract #1901: Rationale and use of single-agent histone deacetylase inhibitor therapy in poorly differentiated midline carcinoma
Matthias Hofer, Daniel Bauer, Stephen Sallan, Brian Schwartz, Michael Cameron, Nathan West, Elin Agoston, Tan Ince, Katherine Janeway, Jon Aster, James Bradner, Christopher French

Cancer Research May 2009, 69 (9 Supplement) 1901;
Abstract #1895: PIK3CA mutation-associated gene expression signature correlates with deactivation of the PI3K pathway and predicts benefit to endocrine therapy in high-risk ER+ (luminal B) breast cancers (BC).
Christos Sotiriou, Sherene Loi, Benjamin Haibe-Kains, Francoise Lallemand, Lajos Pustzai, Alberto Bardelli, Philipe Bedard, Cheryl Gillet, Paul Ellis, Wayne Phillips, Martine Piccart, Grant McArthur

Cancer Research May 2009, 69 (9 Supplement) 1895;
Abstract #1903: Comparative predictive value of E6 mRNA vs. HPV16 ISH for human oropharyngeal carcinoma
W Shi, H Kato, B Perez-Ordonez, M Pintilie, S Huang, A Hui, C How, B OSullivan, J Waldron, P Gullane, L Siu, M Gillison, F-f Liu

Cancer Research May 2009, 69 (9 Supplement) 1903;
Abstract #1893: Predicting the efficacy of anthracyclines in breast cancer (BC): The results of the TOP trial and their validation in the BIG 00-01 trial
Christine Desmedt, Evandro Azambuja, Denis Larsimont, Benjamin Haibe-Kains, Françoise Lallemand, Ghizlane Rouas, Jean Selleslags, Suzette Delaloge, Caroline Duhem, Jean-Pierre Kains, Birgit Carly, Marie Maerevoet, Anita Vindevoghel, Fatima Cardoso, Virginie Durbecq, Jean-Marie Nogaret, Isabelle Veys, Jean-Christophe Schobbens, Danielle Noterman, Roberto Salgado, Angelo Di Leo, Veronique D'Hondt, Martine Piccart, Christos Sotiriou

Cancer Research May 2009, 69 (9 Supplement) 1893;
Abstract #1898: Saliva biomarkers for pancreatic cancer detection
Lei Zhang, James Farrell, Masahiro Sugimoto, Akiyoshi Hirayama, Tomoyoshi Soga, Hui Zhou, David Elashoff, Kai Gao, Bruce Paster, Masaru Tomita, David Wong

Cancer Research May 2009, 69 (9 Supplement) 1898;

Main menu

User menu

Search

More articles from Molecular Markers for Detection and Predicting Therapeutic Response -- Oral Presentations - Proffered Abstracts

Pages

Articles

Info for

About Cancer Research